Peregrine Pharmaceuticals Reports Advances In Bavituximab Clinical Program
 

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients. The trial's planned total of 46 patients has been enrolled and patients are currently undergoing treatment and follow-up.

More...